⚠ Evidence warning: Clinical trials or other evidence do not support the claims that silicon or silicon-rich mineral water protects arteries, lowers arterial stiffness or cardiovascular events, and clears aluminum to protect heart and brain. This page keeps it as a report of what people, websites or other media say.

Silicon for Cardiovascular Health

Elastic layers of the aorta wall
Elastic layers of the aorta wall
Mineral spring water, a source of dissolved silicon
Mineral spring water, a source of dissolved silicon

In 1979, Jean Loeper and colleagues published an autopsy study in Atherosclerosis that has become the foundational observation of the silicon-cardiovascular literature: silicon content of the human aorta declines progressively with age, and the decline is steepest in segments of aorta showing atherosclerotic plaque. A 2024 review tabulates the paper's human figures by plaque burden: 180 micrograms of silicon per 100 mg of nitrogen with no plaques, 105 with 1–2 plaques and 63 with severe disease. Figures in mg per kg of dry tissue (roughly 200 in healthy young aorta, half that in aging healthy aorta, a quarter or less in atherosclerotic segments) are also reported but could not be confirmed against the paper. This was decades before the modern understanding of silicon's role in elastin cross-linking and arterial wall integrity. Subsequent work by Schwarz, Carlisle, Birchall, Powell, and Davenward has built out the mechanistic picture: silicon is essential for the structural quality of arterial elastin, silicon-rich mineral waters increase urinary aluminum excretion (the Davenward 2013 Alzheimer pilot), and population-level silicon intake from drinking water is reported to correlate inversely with cardiovascular event rates in several large European cohorts. This page walks through the elastin-aorta connection, the bottled-water silicon comparison (the surprising result for high-silica volcanic spring water), and the silicon-arterial-stiffness mechanism that ties the loose-skin and brittle-bones story of silicon deficiency to the harder cardiovascular endpoints.


Table of Contents

  1. The Loeper 1979 Aortic Silicon Finding
  2. Elastin Cross-Linking in the Arterial Wall
  3. Arterial Stiffness, Pulse-Wave Velocity, and Silicon
  4. Population Data: Silicon Intake and Cardiovascular Events
  5. Bottled-Water Silicon Concentrations by Type of Water
  6. Aluminum Clearance via Silicon-Rich Mineral Water (Davenward 2013)
  7. The Aluminum-Alzheimer-Cardiovascular Crossover
  8. Vascular Calcification, Silicon, and the K2-D3 Axis
  9. The Cardiovascular Silicon Protocol Practitioners Describe
  10. Cautions
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The Loeper 1979 Aortic Silicon Finding

Jean Loeper was a French cardiovascular researcher at the Hopital Boucicaut in Paris who spent much of his career investigating the chemistry of the arterial wall. His 1979 paper in Atherosclerosis (Loeper, Goy-Loeper, Rozensztajn, Fragny: "The antiatheromatous action of silicon") is reported to describe the silicon content of aortic tissue obtained at autopsy from 35 subjects across the age spectrum, stratified by visible atherosclerotic plaque burden. The paper's PubMed abstract describes only its rabbit experiments: silicon, given into a vein or by mouth, inhibited atheroma in rabbits on an atheromatous diet. The full paper could not be read for this page.

A 2024 review (Dudek and colleagues) tabulates the paper's human aorta figures by plaque burden, not age, as silicon per nitrogen:

The same review also states that aging markedly reduces silicon in normal human aorta. The following figures are also reported for this autopsy series; their units and age bands could not be confirmed against the paper:

The interpretation Loeper proposed was that silicon depletion of the arterial wall is permissive of atherosclerotic lesion development — the silicon-impoverished elastin and collagen of aging aorta is less able to resist the mechanical and chemical insults that initiate plaque formation. Loeper went on to conduct a small clinical trial of silicon supplementation in elderly atherosclerotic patients with some clinical improvement, but the trial was uncontrolled by modern standards.

Aortic silicon decline with age in primate models, and similar findings in rabbit aorta with experimental atherosclerosis, are also reported in writing on silicon. The picture some writers draw is that silicon decline is a signature of aortic aging and that the decline is exaggerated in disease.

What is not known: the studies point in more than one direction. A 1985 study of human aortic intima (the inner lining) measured significantly more silicon in fatty streaks and atheroma than in normal intima, and its authors could not say whether this was a cause or a result of the disease. In a 2015 experiment, female mice bred to develop atherosclerosis were fed a high-fat diet with or without silicon for 15–19 weeks. Silicon levels in blood and aorta were lower in the deprived mice, yet fatty lesions, blood lipids and the structure and mechanics of the aorta did not differ, which the authors describe as “contrary to the reported findings in the cholesterol-fed rabbit model.”

Back to Table of Contents

Elastin Cross-Linking in the Arterial Wall

The aorta and major arteries have a distinctive three-layer wall structure: tunica intima (innermost, endothelial cell monolayer with a thin subendothelial connective tissue layer), tunica media (the muscular middle layer with concentric elastic laminae), and tunica adventitia (the outer collagen-rich connective tissue sheath). The elastic recoil that allows the aorta to expand with each cardiac systole and contract during diastole (the "Windkessel effect" that smooths pulsatile flow into continuous flow) is provided primarily by the elastic laminae of the tunica media.

Each elastic lamina is a sheet of mature elastin produced from tropoelastin monomers cross-linked by lysyl oxidase into the distinctive desmosine and isodesmosine cross-links unique to elastin. The cross-linking process is critical: poorly cross-linked elastin is mechanically weak and degrades rapidly, while well-cross-linked elastin can last decades. Indeed, the half-life of aortic elastin is estimated at 70 years — the elastin you make as a child must largely last a lifetime, because there is essentially no replacement elastin synthesis in the adult cardiovascular system.

Silicon is concentrated in the elastin-rich segments of arterial wall. Its specific role appears to be twofold:

Because adult elastin synthesis is minimal, silicon supplementation in middle and old age cannot create new elastin de novo. But silicon may slow the degradation of existing elastin (by reducing matrix metalloproteinase access) and may improve the function of residual elastin through cross-link stabilization. This explains why silicon-rich diets correlate with lower arterial stiffness even in older adults, when no new elastin is being made.

The implication for prevention is striking: silicon status during childhood, adolescence, and young adulthood — the period when most elastin is laid down — may have outsized effects on cardiovascular outcomes 50 to 70 years later. Children raised on silicon-rich diets (high-grain, mineral-water-rich) may be building a structurally superior elastin scaffold whose mechanical advantages will not become clinically apparent for decades.

Back to Table of Contents

Arterial Stiffness, Pulse-Wave Velocity, and Silicon

Arterial stiffness is a measurable consequence of elastin degradation and is itself a strong independent predictor of cardiovascular events. The standard non-invasive measure is carotid-femoral pulse-wave velocity (PWV) — the speed at which the pressure wave generated by left ventricular systole travels from the carotid artery to the femoral artery. Stiffer arteries propagate the pressure wave faster. A normal young adult has PWV of approximately 6 m/s; an 80-year-old typically has PWV of 12-14 m/s. PWV above 10 m/s is associated with substantially increased cardiovascular event risk.

Arterial stiffness drives cardiovascular disease through several mechanisms:

Writers on silicon report inverse associations between dietary silicon intake and PWV in middle-aged and older adults. They base a causal interpretation on the role attributed to silicon in maintaining the elastin component of the arterial wall, the principal determinant of arterial compliance.

A randomized, double-blind, placebo-controlled trial appeared in 2025: 120 healthy people aged 60–75 took 3.5 g a day of 1% silicon-enriched spirulina or placebo tablets for 6 months. Across the whole group, no measure differed from placebo. In the subgroup with high-normal blood pressure (systolic 130–150 mmHg) and aortic pulse-wave velocity above 10 m/s, blood pressure fell 8% and pulse-wave velocity 13.5%; people below those cut-offs showed no effect. An employee of the company that supplied the tablets is a co-author.

That subgroup result leaves the question open, so no definitive randomized controlled trial of silicon supplementation for arterial stiffness reduction has been published. This represents a clear research opportunity. Proponents regard the available evidence as enough to include silicon adequacy in comprehensive cardiovascular prevention, but not yet enough to establish silicon supplementation as a stand-alone PWV-lowering intervention.

Back to Table of Contents

Population Data: Silicon Intake and Cardiovascular Events

Several European population studies have examined the relationship between drinking-water silicon and cardiovascular outcomes. Drinking water is a tractable population-level silicon exposure because it varies geographically based on local geology and can be quantified relatively easily from public water supply data.

Inverse associations between dietary silicon and arterial stiffness markers are also reported in writing on silicon. The Framingham analysis (Jugdaohsingh et al. 2004), a cross-sectional study of 2,847 people, reports on silicon and bone mineral density; its abstract gives no arterial data.

The aggregate observational evidence is suggestive but not definitive. As with any observational nutritional epidemiology, confounding by overall dietary quality, exercise, socioeconomic factors, and other minerals (calcium, magnesium, fluoride) commonly co-varying with silicon in drinking water cannot be fully ruled out. The case for silicon's cardiovascular role rests on the convergence of observational epidemiology, mechanistic biology (elastin, collagen, aluminum clearance), and biomarker outcomes (arterial stiffness, urinary aluminum) rather than on randomized cardiovascular event-rate trials.

Back to Table of Contents

Bottled-Water Silicon Concentrations by Type of Water

Mineral waters differ widely in silicon. Selected typical concentrations by type of water (from manufacturer-published mineral analyses, not independently verified except where a study is named; values can drift slightly between batches):

One liter per day of either of the two highest-silicon waters above delivers roughly 35–40 mg of elemental silicon — comparable to the approximately 30 mg a day adults take in from food, according to the 2004 Framingham paper. The cost (the highest-silica water at roughly $2-3 per liter in US grocery stores) is real but not prohibitive for the daily-glass use pattern. People following the Davenward protocol for aluminum clearance tend to choose the higher-silicon waters.

The one randomized trial found of the highest-silica water enrolled 17 postmenopausal women with low bone mass, who drank 1 liter a day of it or of purified water for 12 weeks. Urinary silicon rose significantly in the silica-water group (0.016 to 0.037 mg per mg creatinine) and did not change on purified water, showing that the silicon is absorbed. Markers of bone turnover did not change.

Proponents cite the Loeper observation, the Davenward Alzheimer protocol, and the silicon-bone association as independent lines of evidence for modest daily consumption of high-silicon mineral water for long-term health.

Back to Table of Contents

Aluminum Clearance via Silicon-Rich Mineral Water (Davenward 2013)

The 2013 paper by Davenward, Bentham, Wright and colleagues at Keele University (Christopher Exley's group, the most prolific aluminum-toxicity research lab in the world) tested whether dietary silicon could reduce body aluminum burden in patients with Alzheimer's disease. The hypothesis derived from decades of work by Exley's group and others identifying aluminum as a probable contributing factor in Alzheimer's pathology, and from the chemistry that silicic acid forms stable hydroxyaluminosilicate complexes with aluminum ions that are then renally excreted.

The protocol: 15 patients with Alzheimer's disease and a control group of their carers and partners drank up to 1 liter per day of a silicon-rich mineral water (about 35 mg/L as silicic acid, the figure a later study gives for water from the same source) for 12 weeks. Baseline and post-intervention 24-hour urinary aluminum excretion was measured, along with cognitive scores.

The findings:

This was a small open-label proof-of-concept study, not a definitive trial. But it was read as evidence that silicon-rich water functions as a non-invasive systemic aluminum chelator at doses achievable from ordinary consumer mineral water consumption. The cardiovascular implication is that the same mechanism — reducing aluminum body burden — may protect arterial wall structure, since aluminum is itself associated with arterial calcification and arterial wall stiffening.

The Exley group later tried the approach in 15 people with secondary progressive multiple sclerosis (also implicated as an aluminum-related condition by the Exley hypothesis), who drank up to 1.5 liters a day for 12 weeks. Urinary aluminum rose from 135.2 to 349.0 nmol per mmol creatinine, and 14 of the 15 excreted more. The comparison was each person's own 12-week baseline, with no separate control group; the paper reports no relapses and no change in disability scores over the 24 weeks. The water's maker partly funded the study and supplied the water. Proponents describe the cumulative case for silicon-rich mineral water as a chronic, low-burden, dietary aluminum-clearance strategy as reasonably robust.

Back to Table of Contents

The connections between aluminum exposure, Alzheimer's disease, and cardiovascular disease have been built up incrementally over four decades. The summary:

A French study followed 1,925 people aged 65 or over, free of dementia at the start, for up to 15 years. Each extra 10 mg a day of silica from drinking water went with a lower risk of dementia (adjusted relative risk 0.89, P=0.036), and a daily aluminum intake of 0.1 mg or more from water went with greater cognitive decline (P=0.005) and a higher risk of dementia. Geographic exposure to aluminum or silica from tap water was not associated with dementia. This is an observational finding and does not show cause.

Proponents reason that any chronic exposure-reduction strategy aimed at one of these endpoints (cognitive decline, vascular aging) probably benefits the others. They describe silicon-rich mineral water, going without aluminum antiperspirants and aluminum-containing antacids, and replacing aluminum cookware with stainless steel or cast iron as a low-effort, low-cost package with plausible benefits in both domains.

For more on the cognitive side of this story see our Alzheimer's Disease page; for the broader heavy-metals context see our Aluminum page.

Back to Table of Contents

Vascular Calcification, Silicon, and the K2-D3 Axis

One of the modern paradoxes of cardiovascular prevention is that high-dose calcium supplementation may worsen cardiovascular outcomes by promoting vascular calcification, even as it intends to prevent osteoporotic fracture. The Bolland 2010 meta-analysis associated calcium supplements taken without vitamin D with more heart attacks (hazard ratio 1.31, 95% confidence interval 1.02 to 1.67), while its increases in stroke and death were not statistically significant; vitamin K2 was not part of that analysis. Several subsequent studies have also associated calcium supplementation with modest increases in cardiovascular event rates, and proponents hold that the risk is greatest without concurrent vitamin K2.

The proposed mechanism is that excess calcium without adequate K2 to direct it — through carboxylation of osteocalcin (which routes calcium to bone) and matrix Gla protein (which actively inhibits vascular calcification) — ends up in vascular wall calcifications, accelerating arterial stiffening and atherosclerosis. The remedy they describe is twofold: (a) dietary calcium (which is absorbed more gradually and with full cofactor context) in place of high-dose calcium supplements, and (b) adequate vitamin K2 status.

Silicon enters this picture as a third arm of the same axis. Silicon supports the elastin and collagen integrity of the arterial wall, making the wall less susceptible to the calcification process even when calcium is in excess. Silicon thus serves as a brake on vascular calcification analogous to vitamin K2's role — not by directly inhibiting the calcification chemistry, but by preserving the wall structure that resists it.

The integrated cardiovascular protocol that addresses calcium, vitamin D, vitamin K2, magnesium, and silicon together is a more robust prevention strategy than any of these in isolation. This is essentially the same protocol that supports bone density (covered in the Bone Density page) — the bone-cardiovascular overlap is not a coincidence, it reflects the shared connective-tissue biology of both organ systems.

Back to Table of Contents

The Cardiovascular Silicon Protocol Practitioners Describe

The items below report what practitioners describe; the doses are theirs.

Back to Table of Contents

Cautions

This content is provided for informational purposes only and does not constitute medical advice. The safety facts that matter most for a supplement protocol are above: silicon leaves the body through the kidneys, and vitamin K counteracts warfarin.

Back to Table of Contents

Key Research Papers

  1. Loeper J, Goy-Loeper J, Rozensztajn L, Fragny M (1979). The antiatheromatous action of silicon. Atherosclerosis. — PubMed PMID: 508383
  2. Davenward S, Bentham P, Wright J et al. (2013). Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease. Journal of Alzheimer's Disease. — PubMed PMID: 22976072
  3. Schwarz K (1973). A bound form of silicon in glycosaminoglycans and polyuronides. Proceedings of the National Academy of Sciences. — PubMed PMID: 4268099
  4. Jugdaohsingh R, Tucker KL, Qiao N et al. (2004). Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort. Journal of Bone and Mineral Research. — PubMed PMID: 14969400
  5. Birchall JD, Chappell JS (1988). The chemistry of aluminum and silicon in relation to Alzheimer's disease. Clinical Chemistry. — PubMed PMID: 2830051
  6. Exley C (2009). Darwin, natural selection and the biological essentiality of aluminium and silicon. Trends in Biochemical Sciences. — PubMed PMID: 19773172
  7. Sripanyakorn S, Jugdaohsingh R, Elliott H et al. (2004). The silicon content of beer and its bioavailability in healthy volunteers. British Journal of Nutrition. — PubMed PMID: 15005826
  8. Powell JJ, McNaughton SA, Jugdaohsingh R et al. (2005). A provisional database for the silicon content of foods in the United Kingdom. British Journal of Nutrition. — PubMed PMID: 16277785
  9. Bissé E, Epting T, Beil A et al. (2005). Reference values for serum silicon in adults. Analytical Biochemistry. — PubMed PMID: 15649385
  10. Bolland MJ, Avenell A, Baron JA et al. (2010). Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. — PubMed PMID: 20671013
  11. Schurgers LJ, Spronk HMH, Soute BAM et al. (2007). Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. — PubMed PMID: 17138823
  12. Virsolvy A, Benmira AM, Allal S et al. (2025). Benefits of dietary supplementation with specific silicon-enriched spirulina on arterial function in healthy elderly individuals: a randomized, placebo-controlled trial. Nutrients. — PubMed PMID: 40077730
  13. Dudek Ł, Kochman W, Dziedzic E (2024). Silicon in prevention of atherosclerosis and other age-related diseases. Frontiers in Cardiovascular Medicine. — PubMed PMID: 38495942
  14. Nakashima Y, Kuroiwa A, Nakamura M (1985). Silicon contents in normal, fatty streaks and atheroma of human aortic intima: its relationship with glycosaminoglycans. British Journal of Experimental Pathology. — PubMed PMID: 3970827
  15. Jugdaohsingh R, Kessler K, Messner B et al. (2015). Dietary silicon deficiency does not exacerbate diet-induced fatty lesions in female ApoE knockout mice. Journal of Nutrition. — PubMed PMID: 25972522
  16. Schwarz K, Ricci BA, Punsar S, Karvonen MJ (1977). Inverse relation of silicon in drinking water and atherosclerosis in Finland. Lancet. — PubMed PMID: 65628
  17. Li Z, Karp H, Zerlin A et al. (2010). Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study. Nutrition Journal. — PubMed PMID: 20946656
  18. Jones K, Linhart C, Hawkins C, Exley C (2017). Urinary excretion of aluminium and silicon in secondary progressive multiple sclerosis. EBioMedicine. — PubMed PMID: 29128442
  19. Rondeau V, Jacqmin-Gadda H, Commenges D et al. (2009). Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. American Journal of Epidemiology. — PubMed PMID: 19064650

PubMed Topic Searches

  1. PubMed: silicon + atherosclerosis + aorta
  2. PubMed: silicon + arterial stiffness
  3. PubMed: silicon mineral water + aluminum
  4. PubMed: vascular calcification + K2 + MGP
  5. PubMed: elastin cross-link + arterial aging

Back to Table of Contents

Connections

Back to Table of Contents